Typhoid Vi Polysaccharide Vaccine

PreclinicalVaccine

Typhoid Vi Polysaccharide Vaccine is one of 19 biologic programs targeting Japanese encephalitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

Japanese EncephalitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Japanese Encephalitis

#DrugCompanyPhaseTrials

Hepatitis a Vaccine

Sanofi

Phase 3

1 2

Prevnar

GSK

Phase 3

1 3

Havrix

GSK

Phase 3

1 4

Measles Vaccine

GSK

Phase 3

1 5

Rituxan

Roche

Phase 2

—6

Measles-Mumps-Rubella Vaccine

LLiaoning Chengda Biotechnology CO., LTD

Approved

2 7

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

1 8

Varicella Vaccine

Sanofi

Phase 3

1 9

Immunoglobulin

Sanofi

Phase 2

1 10

Rabies

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Prophylaxis

NCT05745987

Q4 2028

Phase 1Recruiting

Fear

NCT06630884

Clinical

Trials by Indication[1]

Inflammation2 trials

Inflammation and Threat Sensitivity in PTSD

Completed·UUniversity of California, San Francisco·Phase 1·NCT03048929·30 enrolled

Cognitive, Emotional, and Neural Responses to Acute Inflammation

Completed·UUniversity of California, San Francisco·Phase 1·NCT03294564·24 enrolled

Japanese encephalitis1 trial

Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity

Unknown status·UUniversity of Oxford·N/A·NCT06027801·150 enrolled

Fear1 trial

Inflammatory Challenge and Fear

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT06630884·288 enrolled

Prophylaxis1 trial

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

Recruiting·MMcMaster University·Phase 4·NCT05745987·3,000 enrolled

Immunogenicity1 trial

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed· Novartis logo

Novartis·Phase 3·NCT01466387·552 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Typhoid Vi Polysaccharide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Typhoid Vi Polysaccharide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Typhoid Vi Polysaccharide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: Novartis

Typhoid Vi Polysaccharide Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Inflammation2 trials

Japanese encephalitis1 trial

Fear1 trial

Prophylaxis1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News